secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001437749-24-015074
Event type: m_and_a
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO Health to sell BioReference assets to Labcorp for $237.5M; Q1 net loss $81.8M
--------------------------------------------------------------------------------

- Agreed to sell select BioReference Health assets to Labcorp for $237.5M; assets generate ~$100M annual revenue; closing expected H2 2024.
- Q1 total revenue $173.7M (down 27% YoY); net loss $81.8M ($0.12/share) vs $18.3M loss a year ago.
- Issued $230M 3.75% convertible notes due 2029; exchanged $144.4M of existing 4.50% notes; used $50M to repurchase common stock.
- FDA cleared IND for MDX2001 tetraspecific antibody for solid tumors; Phase 1 trial enrollment expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000143774924015074/0001437749-24-015074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000143774924015074/opk20240503_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-015074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer